Motif Bio Share Discussion Threads

[oilisgold] 14/2/2019 13:32

some ARE SAYING FEW TWEEKS, but I think those TRADERS have no idea how the approval works.

[oilisgold] 14/2/2019 13:31

Ignore those RAMPERS ON LSE. Its a complete Response letter, so no chance of approval. Clinical studies take a long time and require lot of money. Get out whilst you can.

[1bond] 14/2/2019 13:28

Here is some research for you going back to 2009.

Do you really think the FDA will approve this drug when its been turned down twice?

[pyglet] 14/2/2019 13:14

Looks like 10 is a ceiling for now.

[glenbo1] 14/2/2019 13:11

You are talking utter nonsense pal.3 stages of clinical.trials.Do some research please.

[sunnybeachboy] 14/2/2019 13:10

New target 14p.

[1bond] 14/2/2019 13:01

The Company should publish the CRL in full but it won't want shareholders to know the full list of deficiencies cited by the FDA. More clinical trials will be needed if the company was to get approval. More cash, no shareholder support so very unlikely to survive.

[tomboyb] 14/2/2019 13:01

It seems Dave that anyone is allowed on these BBs these days esp "rifraf" like letmepass -

[knowing] 14/2/2019 13:00

It's like a feeding frenzy. Off to buy some PFC and TUI with my profits

[timw3] 14/2/2019 12:53

will open up at 10p+ on the Nasdaq

[kirk 6] 14/2/2019 12:52

28k up offloading a few now

[robizm] 14/2/2019 12:46

Liver toxicity is surely something that comes out before you do stage 2 and 3. No expert on Bio stocks but wish the company would do an interview. Surely they must have been ready to do interviews if it had passed

[timw3] 14/2/2019 12:45

Mausaeus
‏

@Mausaeus
2m2 minutes ago
More
People need to understand what a FDA CRL is. It's a list of correctable concerns. Nothing more. #MTFB

[sunnybeachboy] 14/2/2019 12:44

Dont argue with the parasites peeps. Its not worth it. We know the large sellers are cleR and this is going above 10p

[timw3] 14/2/2019 12:43

From #MTFB...”The CRL states that the FDA cannot approve the NDA in its present form and indicates that additional data are needed”

Ok so “current form” is the saving grace here!

Also $12m cash in bank...

suspect people going to pile in as penny drops all not that bad!

[timbo003] 14/2/2019 12:41

>>>>Banshee

I'm not sure about that, it would be unusual to ask for long term follow up data for a drug which is only for short term use?

[banshee] 14/2/2019 12:38

The best case scenario is that the FDA want long term follow up data on liver function for the 2 revive trials imo, it is very unlikely they want toxicity data already in Motif's possession as that should all have been submitted, given the problems the previous owner of Iclaprim experienced, unless Motif and their consultants are totally incompetent.

Worst case, and rather higher probability imo, is that the FDA want new trial(s), if only on toxicity. Heaven knows how many patients this would require if the existing numbers are not enough. This would mean resubmission is 2-3 years or so away and would be very high risk and require a lot of money. IMO if motif try and raise cash before their FDA meeting that will be an indication to set your expectations low. The share price may well bounce but the chance that the company is worth nothing is now considerable.

[tomboyb] 14/2/2019 12:34

I wonder if someone could possible make a bid offer here -

If this can resolved then the upside is huge -

[timw3] 14/2/2019 12:34

#MTFB It was 40p due to a label issue 😂 nothing wrong with the phase three drug, what a fantastic trade. Soon be back where it was no problem 👍
0 replies 1 retweet 1 like

[pyglet] 14/2/2019 12:34

A lot of people have made a lot of money here today